why choose us

Clinical Trials Search

Showing 7,660 of 132,963 result(s)
Effect of NUTRICAN to Improve Nutritional Status in Cancer Patients

Status: Completed

Condition: Malnutrition; Protein

Interventions: Per serving;sachet NUTRICAN (±81g) contains 350 kcal energy, 9 g fat, 20 g protein, 48 g carbohydrate, 400 mg DHA, 300 mg EPA, 0.92 g Omega-3, 1

Date: 2023-10-23

Study of B;F;TAF in Participants Switching From CAB + RPV to B;F;TAF for HIV-1 Infection (EMPOWER)

Status: Completed

Condition: HIV-1-infection

Interventions: Tablets administered without regard to food

Date: 2023-10-23

Radicle Recharge: A Study of Health and Wellness Products on Energy Levels and Other Health Outcomes

Status: ACTIVE_NOT_RECRUITING

Condition: Energy

Interventions: Participants will use their Radicle Recharge Placebo Control 1 as directed for a period of 5 hours.

Date: 2023-10-23

Biennial CEM in Women With a Personal History of Breast Cancer

Status: Completed

Condition: Breast Cancer

Interventions: Contrast-enhanced mammography (CEM) is a new FDA-approved exam that is similar to magnetic resonance imaging (MRI) in depicting breast cancers due to

Date: 2023-10-23

Health-Related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab

Status: NOT_YET_RECRUITING

Condition: Hemophilia A

Interventions: Emicizumab in Hemophilia A

Date: 2023-10-23

Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis

Status: Completed

Condition: Toxic Epidermal Necrolysis

Interventions: Solu-Medrol® 1 mg;kg body weight intravenous infusion per day in combination with Arocitinib tablets 200 mg per day for 2 weeks

Date: 2023-10-23

Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1568 in Healthy Adult Volunteers

Status: Completed

Condition: Healthy Volunteers

Interventions: One tablet of DWJ1568

Date: 2023-10-23

Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects

Status: Completed

Condition: Drug Drug Interaction

Interventions: Experimental Drug 1

Date: 2023-10-23

Effects of the Shared-decision Making Training Program

Status: COMPLETED

Condition: Competence

Interventions: A 20-hour tailored SDM combined with EBP training program consisting of a seven-hour lecture and a four-hour hands-on practice session.

Date: 2023-10-23

Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Status: Completed

Condition: Systemic Lupus Erythematosus

Interventions: Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Date: 2023-10-23